Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$75.02 USD

75.02
1,449,518

+0.07 (0.09%)

Updated May 17, 2024 04:00 PM ET

After-Market: $75.00 -0.02 (-0.03%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal

by Zacks Equity Research

Cynosure, Inc. (CYNO), announced that it has entered into a definitive merger agreement with Hologic, Inc. (HOLX).

    Hologic (HOLX) Beats on Q1 Earnings, Lowers '17 Guidance

    by Zacks Equity Research

    Hologic Inc. (HOLX) reported first-quarter fiscal 2017 adjusted earnings per share (EPS) of 52 cents, up 13% year over year.

      Medical Instrument Stocks' Earnings on Feb 1: EW, HOLX, BABY

      by Zacks Equity Research

      Already more than one-third of the S&P 500 members (170 companies making up for 19.2% of the total market cap) have reported their Oct--Dec 2016 quarter's earnings results.

        John Blank headshot

        4 Good Reasons to Focus on the USA: Global Week Ahead

        by John Blank

        In the Global Week Ahead, the bulk of any trader???s time should focus on the good ol' USA. Why do we think that? There are four old-fashioned reasons.

          Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3

          by Zacks Equity Research

          Abiomed Inc. (ABMD) reported third-quarter fiscal 2017 earnings of 34 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and surged 47.8% from the year-ago quarter.

            C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected

            by Zacks Equity Research

            C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.

              Quality Systems (QSII) Beats on Earnings & Revenues in Q3

              by Zacks Equity Research

              Irvine, CA-based Quality Systems Inc. (QSII) reported third-quarter fiscal 2017 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 18 cents.

                Varian Medical (VAR) Misses on Q1 Earnings and Revenues

                by Zacks Equity Research

                Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 75 cents per share in the first quarter of fiscal 2017.

                  McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal

                  by Zacks Equity Research

                  McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.

                    Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance

                    by Zacks Equity Research

                    Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate by 2 cents.

                      Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues

                      by Zacks Equity Research

                      Intuitive Surgical Inc. (ISRG) posted adjusted earnings of $5.30 per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate by four cents.

                        Is a Surprise in Store for Hologic (HOLX) in Q1 Earnings?

                        by Zacks Equity Research

                        Hologic Inc. (HOLX) is slated to report first-quarter fiscal 2017 financial results on Feb 1, after the closing bell.

                          The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic

                          by Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic

                            3 Medical Device Stocks Likely to Beat Earnings Estimates

                            by Zacks Equity Research

                            The likely revocation of the 2.3% medical device excise tax is going to be a big bonus for both the behemoths and small players.

                              Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay

                              by Zacks Equity Research

                              Hologic, Inc. (HOLX) recently announced the receipt of the FDAs Premarket Approval (PMA) for its Aptima HIV-1 Quant assay.

                                Hologic (HOLX) to Divest Blood Screening Business to Grifols

                                by Zacks Equity Research

                                Hologic, Inc. (HOLX) recently inked a deal to divest its stake in the blood screening business.

                                  Hologic Hits 52-Week High on Q4 Earnings & Solid Prospects

                                  by Zacks Equity Research

                                  Share price of Bedford, MA-based Hologic Inc. (HOLX) reached a new 52-week high of $41.01 on Dec 14, finally closing a tad lower at $40.79.

                                    Whole Foods (WFM) Will No Longer be Part of Nasdaq-100

                                    by Zacks Equity Research

                                    As a result of the annual re-ranking of the NASDAQ-100 index, Whole Foods (WFM) will cease to be a part of the same.

                                      Bed Bath and Beyond (BBBY) Loses its Place in Nasdaq-100

                                      by Zacks Equity Research

                                      The NASDAQ-100 Index as part of its annual re-ranking process has decided to remove Bed, Bath & Beyond Inc. (BBBY).

                                        4 Medical Instrument Stocks to Bet on This Earnings Season

                                        by Zacks Equity Research

                                        The medical instrument sector holds a lot of promise at this moment.

                                          Top 3 MedTech Stocks Poised to Gain this Earnings Season

                                          by Zacks Equity Research

                                          A bipartisan group of ten senators signed on a bill to repeal the 2.3% federal excise tax on medical device makers.